684 related articles for article (PubMed ID: 16741311)
1. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
[TBL] [Abstract][Full Text] [Related]
2. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
3. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
[TBL] [Abstract][Full Text] [Related]
4. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
[TBL] [Abstract][Full Text] [Related]
5. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
[TBL] [Abstract][Full Text] [Related]
6. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
[TBL] [Abstract][Full Text] [Related]
7. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
Mairs RJ; Ross SC; McCluskey AG; Boyd M
J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
[TBL] [Abstract][Full Text] [Related]
8. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
[TBL] [Abstract][Full Text] [Related]
9. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy.
Boyd M; Mairs SC; Stevenson K; Livingstone A; Clark AM; Ross SC; Mairs RJ
J Gene Med; 2002; 4(5):567-76. PubMed ID: 12221650
[TBL] [Abstract][Full Text] [Related]
10. Study on cell survival, induction of apoptosis and micronucleus formation in SCL-II cells after exposure to the auger electron emitter (99m)Tc.
Kriehuber R; Kadenbach K; Schultz F; Weiss DG
Int J Radiat Biol; 2004; 80(11-12):875-80. PubMed ID: 15764396
[TBL] [Abstract][Full Text] [Related]
11. Effects of low and high LET radiations on bystander human lung fibroblast cell survival.
Baskar R; Balajee AS; Geard CR
Int J Radiat Biol; 2007 Aug; 83(8):551-9. PubMed ID: 17613128
[TBL] [Abstract][Full Text] [Related]
12. Targeted radiotherapy: microgray doses and the bystander effect.
Mairs RJ; Fullerton NE; Zalutsky MR; Boyd M
Dose Response; 2007 Apr; 5(3):204-13. PubMed ID: 18648605
[TBL] [Abstract][Full Text] [Related]
13. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
[TBL] [Abstract][Full Text] [Related]
15. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Mairs RJ; Boyd M
Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
[TBL] [Abstract][Full Text] [Related]
16. Effect of dose rate on the radiation-induced bystander response.
Gow MD; Seymour CB; Byun SH; Mothersill CE
Phys Med Biol; 2008 Jan; 53(1):119-32. PubMed ID: 18182691
[TBL] [Abstract][Full Text] [Related]
17. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.
Carlsson J; Eriksson V; Stenerlöw B; Lundqvist H
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1185-95. PubMed ID: 16718515
[TBL] [Abstract][Full Text] [Related]
18. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons.
Michel RB; Castillo ME; Andrews PM; Mattes MJ
Clin Cancer Res; 2004 Sep; 10(17):5957-66. PubMed ID: 15355929
[TBL] [Abstract][Full Text] [Related]
19. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells.
Baierlein SA; Distel L; Sieber R; Weiss C; Rödel C; Sauer R; Rödel F
Strahlenther Onkol; 2006 Aug; 182(8):467-72. PubMed ID: 16896593
[TBL] [Abstract][Full Text] [Related]
20. Concerning the health effects of internally deposited radionuclides.
Raabe OG
Health Phys; 2010 Mar; 98(3):515-36. PubMed ID: 20147792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
